Biomarker Analysis of Zanubrutinib and Tislelizumab Combination Therapy in Patients with Relapsed/Refractory B-Cell Malignancies

Background/Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma world-wide. Although frontline therapies have yielded positive outcomes in most patients with DLBCL, about one-third of patients are refractory to or relapse after standard therapy (Sehn et al. J Clin Oncol 2005;23(22):5027-33). The antitumor efficacy of zanubrutinib and tislelizumab combination therapy has been demonstrated in patients with B-cell malignancies (Tam et al. Blood 2019;134:1594). Herein, we performed a comprehensive analysis to examine biomarkers associated with response or resistance to zanubrutinib and tislelizumab combination therapy in patients with B-cell malignancies.

Methods: Biomarker analysis was performed in 24 patients with published response data determined by the investigator using Lugano 2014 criteria (Cheson et al. J Clin Oncol 2014;32(27):3059-68). Programmed death-ligand 1 (PD-L1) gene amplification was assessed in the baseline tumor of 11 patients with non-germinal center B-cell (GCB) subtype of DLBCL by fluorescence in situ hybridization (Empire Genomics). PD-L1 protein expression was examined in the baseline tumor (8 DLBCL) by immunohistochemistry (IHC) (Ventana PD-L1 [SP263] assay; Roche). DLBCL subtype and gene expression were examined in the baseline tumor (14 DLBCL) by HTG EdgeSeq DLBCL cell of origin assay (HTG Molecular Diagnostics). Gene mutation was examined in the baseline tumor (17 DLBCL) by DNA-seq (CGI NGS 220-Gene Panel assay; Cancer Genetic Inc.). PD-L1 and CD8 protein expression were examined in paired biopsy samples (1 DLBCL, 3 transformed follicular lymphoma [tFL], 1 follicular lymphoma [FL], 1 mantle cell lymphoma) before and 8 days after zanubrutinib treatment by IHC (Ventana SP263, CONFIRM CD8 SP57). Gene expression profiles were examined in paired biopsy samples (3 tFL, 1 FL, 1 chronic lymphocytic leukemia) by RNA-seq (RNA Access assay; Illumina).

Results:PD-L1 gene alteration was observed in 2 of 11 patients with non-GCB DLBCL, including 1 with gene amplification and 1 with chromosome 9 polysomy. A higher overall response rate (ORR; 2/2 [100%] vs 3/9 [33.3%]) and complete response (CR) rate (2/2 [100%] vs 2/9 [22.2%]) was observed in patients with PD-L1 gene alteration than in patients without. Two of 8 [25%] evaluable patients with DLBCL harbored PD-L1⁺ tumor cells (defined using a PD-L1 protein expression cut-off ≥1%). A higher ORR (1/2 [50%] vs 2/6 [33%]) and CR rate (1/2 [50%] vs 1/6 [16.7%]) was observed in patients with PD-L1⁺ tumor cells than in those without. High mRNA levels of CD3D (P < 0.05), HLA-DRA (P < 0.07), and LAG3 (P < 0.05) were enriched in responders, suggesting an inflamed tumor microenvironment (TME). In contrast, non-responders harbored high mRNA levels of the NF-kB pathway-related gene REL (P < 0.05). High mRNA levels of REL were associated with an inferior clinical outcome to zanubrutinib and tislelizumab combination therapy (P < 0.05). Mutations in the tumor suppressor gene TP53 (5/10 [50%] vs 0/7 [0%]) were enriched in non-responders. Non-responders harbored higher frequency of mutations in genesinvolved in immune evasion (3/10 [30%] vs 1/7 [14.3%]), epigenetic modifications (2/10 [20%] vs 1/7 [14.3%]), and cell survival (2/10 [20%] vs 0/7 [0%]) than responders, suggesting that non-responders may have complex resistance mechanisms. Results from paired tumor biopsies from 5 patients before and after zanubrutinib treatment revealed that zanubrutinib treatment downregulated B-cell and MYC target-related gene sets and upregulated the NK cell-related gene set NK-2. Zanubrutinib treatment seemed to have no effect on the frequency of PD-L1⁺ cells and CD8⁺ T cells (using a CD8 expression cutoff of ≥1%) in the TME, although the sample size was too small to draw a definitive conclusion.

Conclusion: Patients with PD-L1 gene amplification, PD-L1⁺ tumor cells, and high mRNA levels of CD3D, HLA-DRA, and LAG3 in baseline tumor tissue may be more responsive to zanubrutinib and tislelizumab combination therapy. A high mRNA level of REL or mutations in TP53 may contribute to resistance of zanubrutinib and tislelizumab combination therapy. Due to the limited number of samples, results must be interpreted with caution.

Ma:BeiGene: Current Employment, Current equity holder in publicly-traded company. Huang:BeiGene: Current Employment. Zhao:RiboX Therapeutics, Ltd.: Current Employment, Current holder of stock options in a privately-held company; BeiGene: Ended employment in the past 24 months. Yu:BeiGene: Ended employment in the past 24 months; BMS: Current Employment. Puig:BeiGene: Current Employment, Current equity holder in publicly-traded company; Eli Lilly: Ended employment in the past 24 months. Liu:BeiGene (Shanghai) Co., Ltd: Current Employment, Current equity holder in publicly-traded company. Hilger:BeiGene: Current Employment, Current equity holder in private company, Current holder of stock options in a privately-held company, Divested equity in a private or publicly-traded company in the past 24 months.